S1660
Physics - Detectors, dose measurement and phantoms
ESTRO 2026
617 radioligand therapy. At present, standardized treatments protocols do not consider patient-specific biokinetics variability, often leading to widespread undertreatment. Accurate dosimetry is therefore essential, but it currently relies on multiple Single Photon Emission Computed Tomography (SPECT) which are resource-demanding and challenging for patients. The TRONDHEIM project (specT foR prOstate caNcer treateD witH 177-lutEtIuM) aims to develop wearable dosimeter allowing to retrieve the time- activity washout curve (TAC), paving the way for personalized treatments. Material/Methods: The system is made by a cylinder of 25 mm diameter and 5 mm thick, of plastic scintillators doped with high-Z elements. This approach exploits the fast scintillation characteristics and the versatility of organic scintillators with an increased photoelectric interaction probability with respect to traditional plastic scintillators. Thus, will allow for a temporal evolution monitoring of the radiotracer in the patient. Monte Carlo (MC) simulations have been performed to optimise the crucial parameters, such as the positioning of the detector(s), and to find the optimal configuration that enables the activity distribution monitoring. In MC, 177Lu photons have been produced according to an activity distribution of a real SPECT exam, and the scoring of deposited energy has been used to reconstruct a counting rate map. Results: Significant progress has been achieved in the synthesis and patenting of new organic fluorophores used in scintillator composition, doped samples with concentrations up to 10% of Bismuth have been produced and characterised (commercial samples have been used as reference). A custom readout and preprocessing system based on SiPM arrays has been developed and preliminary characterised. Conclusion: The TRONDHEIM project demonstrates encouraging progress toward the realization of compact, wearable dosimeter based on innovative doped organic scintillators for personalized dosimetry in theranostic applications. Together with the retrieving of patient- specific biokinetics and TAC based on MC simulations, this project provides for a solid foundation that paves the way to a new paradigm by shifting to patient- centered monitoring system. By combining wearable technology and computational optimization, it will enable a shift from standardized dosing to adaptive strategies that optimize therapeutic efficacy. Keywords: Theranostic, Dosimetry, Wearable detectors
Conclusion: The combined alanine–EBT-XD film dosimeter provides a promising and traceable approach for in vivo dosimetry in preclinical FLASH experiments. It shows good agreement with diamond detector measurements and causes minimal perturbation of the local dose distribution, supporting its use in large animal models such as mini pigs and in future clinical FLASH studies. Keywords: FLASH, In vivo dosimetry Theranostic study for 177 Lu-PSMA-617 treatment optimization in metastatic Castration Resistant Prostate Cancer (mCRPC): the TRONDHEIM project Arianna Vannucci 1,2 , Mattia Bonuso 1 , Alberto Burattini 2,3 , Marina Carruezzo 3,4 , Maria Silvia De Feo 5 , Giuseppe De Vincentis 5 , Gaia Franciosini 3,4 , Viviana Frantellizzi 5 , Laura Frassi 6 , Marco Garbini 1 , Marco Magi 3,4 , Leonardo Mattiello 3 , Vincenzo Patera 3,4 , Flaminia Quattrini 6,4 , Alessio Sarti 3,4 , Angelo Schiavi 3,4 , Luana Testa 6,1 , Marco Toppi 3,4 , Giacomo Traini 4 , Michela Marafini 1,4 Digital Poster 2999 1 Department of Physics, “Enrico Fermi” Historical Museum of Physics and Study and Research Centre (CREF), Rome, Italy. 2 Post-graduate School in Medical Physics, Sapienza University of Rome, Rome, Italy. 3 Department of Basic and Applied Sciences for Engineering, Sapienza University of Rome, Rome, Italy. 4 Roma I Section, National Institute for Nuclear Physics (INFN), Rome, Italy. 5 Department of Radiology, Oncology and Anatomo-Pathology, Sapienza University of Rome, Rome, Italy. 6 Department of Physics, Sapienza University of Rome, Rome, Italy Purpose/Objective: Theranostics, an important area in nuclear medicine, leverages radionuclides for both imaging and therapy, with Lutetium-177 emerging as a key candidate for studies in metastatic Castration Resistant Prostate Cancer (mCRPC) patients treated with 177Lu-PSMA-
Made with FlippingBook - Share PDF online